VIVACTIL (protriptyline hydrochloride) by Teva is clinical pharmacology protriptyline hydrochloride is an antidepressant agent. Approved for symptoms of mental depression in patients. First approved in 1967.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
VIVACTIL (protriptyline hydrochloride) is a tricyclic antidepressant approved in 1967 for treating symptoms of mental depression. It works through an unknown mechanism distinct from monoamine oxidase inhibition, with a notably rapid onset of action (within one week) and minimal sedative properties. The drug is administered orally as a tablet and has slow excretion kinetics.
As a legacy antidepressant approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely consolidating resources toward maintenance rather than expansion.
CLINICAL PHARMACOLOGY Protriptyline hydrochloride is an antidepressant agent. The mechanism of its antidepressant action in man is not known. It is not a monoamine oxidase inhibitor, and it does not act primarily by stimulation of the central nervous system. Protriptyline has been found in some…
Working on VIVACTIL offers limited career acceleration; the product is in decline phase with minimal market expansion or innovation initiatives. Roles available are primarily maintenance-focused, supporting a shrinking customer base and managing generic transition.
Worked on VIVACTIL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.